Edition:
United States

Medtronic PLC (MDT)

MDT on New York Consolidated

81.00USD
24 Mar 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$81.00
Open
--
Day's High
--
Day's Low
--
Volume
4
Avg. Vol
6,157,785
52-wk High
$89.27
52-wk Low
$69.35

MDT

Chart for MDT

About

Medtronic Public Limited Company (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group,... (more)

Overall

Beta: 1.02
Market Cap(Mil.): $110,879.70
Shares Outstanding(Mil.): 1,368.89
Dividend: 0.43
Yield (%): 2.12

Financials

  MDT Industry Sector
P/E (TTM): 28.59 34.18 29.94
EPS (TTM): 2.83 -- --
ROI: 4.42 12.74 13.01
ROE: 7.92 14.79 14.16

BRIEF-Medtronic receives FDA approval for corevalve evolut pro transcatheter valve with advanced sealing

* Medtronic receives fda approval for corevalve(tm) evolut(tm) pro transcatheter valve with advanced sealing

Mar 22 2017

BRIEF-Medtronic announces pricing of $2 billion of senior notes

* REG-Medtronic announces pricing of $2 billion of senior notes

Mar 21 2017

BRIEF-Medtronic says data from surtavi trial showed co's self-expanding TAVR platform met primary endpoint at 2 years

* Landmark surtavi clinical trial shows transcatheter aortic valve replacement (tavr) with the self-expanding platform performs as well as surgery in intermediate risk severe aortic stenosis patients

Mar 17 2017

Medtronic heart valve replacement succeeds in intermediate-risk patients: study

WASHINGTON Medtronic Plc's non-invasive transcatheter aortic valve replacement (TAVR) system proved as safe as traditional surgery in intermediate-risk patients in a two-year study presented on Friday, paving the way for its use in a wider patient population.

Mar 17 2017

Medtronic heart valve replacement succeeds in intermediate-risk patients-study

WASHINGTON, March 17 Medtronic Plc's non-invasive transcatheter aortic valve replacement (TAVR) system proved as safe as traditional surgery in intermediate-risk patients in a two-year study presented on Friday, paving the way for its use in a wider patient population.

Mar 17 2017

U.S. medtech shares gain as investors seek shelter from drug price debate

NEW YORK Investors are seeking shelter in shares of U.S. medical device and supply companies, encouraged by their solid growth prospects and wary that President Donald Trump's criticism of drug prices makes owning pharmaceutical and biotechnology stocks risky.

Mar 13 2017

U.S. medtech shares gain as investors seek shelter from drug price debate

NEW YORK, March 13 Investors are seeking shelter in shares of U.S. medical device and supply companies, encouraged by their solid growth prospects and wary that U.S. President Donald Trump's criticism of drug prices makes owning pharmaceutical and biotechnology stocks risky.

Mar 13 2017

BRIEF-Medtronic receives FDA clearance for Reveal Linq(TM) ICM with trurhythm(TM) detection

* Medtronic receives FDA clearance for reveal linq(tm) insertable cardiac monitor (icm) with trurhythm(tm) detection Source text for Eikon: Further company coverage:

Mar 13 2017

BRIEF-Medtronic launches study for below-the-knee peripheral arterial disease

* Medtronic-Launch of IN.PACT BTK study to evaluate effectiveness of using drug-coated balloon in patients with below-the-knee peripheral arterial disease

Mar 09 2017

BRIEF-Medtronic receives CE mark for next generation cardiac resynchronization therapy-pacemakers

* Medtronic receives CE mark for its next generation cardiac resynchronization therapy-pacemakers Source text for Eikon: Further company coverage:

Feb 24 2017

More From Around the Web

Earnings vs. Estimates